|
41 |
Anti-Angiogenics: Their Role in the Treatment of Glioblastoma
Enthalten in Oncology research and treatment Bd. 41, 2018, Nr. 4: 181-186
|
|
|
|
42 |
What's New in Grade II and Grade III Gliomas?
Enthalten in Seminars in neurology Bd. 38, 2018, Nr. 01: 041-049
|
|
|
|
43 |
Neue Behandlungsoptionen bei Gliomen
Enthalten in Der Onkologe 14.11.2018: 1-7
|
|
|
|
44 |
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma
Enthalten in Acta neuropathologica 5.9.2018: 1-11
|
|
|
|
45 |
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations
Enthalten in Acta neuropathologica 21.3.2018: 1-19
|
|
|
46 |
Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine
Capper, David. - Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2017
|
|
|
|
47 |
Neuroonkologische Zentren (NOZ)
Enthalten in Aktuelle Neurologie Bd. 44, 2017, Nr. 01: 8-14
|
|
|
|
48 |
Immuntherapien bei Gliomen
Enthalten in Der Onkologe 13.7.2017: 1-7
|
|
|
|
49 |
Suppression of Th1 differentiation by tryptophan supplementation in vivo
Enthalten in Amino acids 18.4.2017: 1-7
|
|
|
|
50 |
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Enthalten in Acta neuropathologica 25.1.2017: 1-16
|
|
Administration
